Skip to content

Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile

September 18, 2026 · 35 min

Show notes

On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets.
Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition, noting deals such as Blackstone's with Alnylam and Apogee can reduce dilution and extend runway.

View full story: https://www.biocentury.com/article/660824

#Biotech #PrivateEquity #DrugDevelopment #LifeSciences #ClinicalTrials

0:00 Introduction
1:22 New Fund & Founding
10:30 Alnylam Deal
17:14 Working with Big Caps
25:54 Biotech Risk
29:13 China

All episodes of The BioCentury Show

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.